Alzheimer's Disease and Related Disorders (MERE)

March 14, 2011 updated by: University Hospital, Angers

Maladie d'Alzheimer et Maladies apparentées : Caractérisation Des Anomalies Cognitivo-motrices, et Des Effets Des médicaments Anti-démence et de la Vitamine D à Partir de la Mise en Place d'Une Base de données au CMRR du CHU d'Angers

The purpose of this study is to compare characteristics of gait and balance measured among patients with Alzheimer's disease or related disorders separated into 3 groups according to the stage of disease (i.e., pre-dementia, mild and moderate dementia stages); to determine the effects of anti-dementia drugs and vitamin D on cognitive motor abnormalities; and to establish a database at Angers University Memory Centre.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

Although gait disorders are frequently associated with Alzheimer's disease and related disorders (ADRD), few studies have focused on cognitive motor effects of anti-dementia drugs and vitamin D.

The objectives of this study are to

  • Compare characteristics of gait and balance measured among patients with ADRD separated into 3 groups according to stages of disease (i.e., pre-dementia, mild and moderate dementia stages)
  • To determine the effects of anti-dementia drugs and vitamin D on cognitive motor abnormalities
  • To determine whether motor abnormalities could be associated with cognitive impairments, specifically executive dysfunctions
  • To establish a database at Angers University Memory Center.

Study Type

Observational

Enrollment (Anticipated)

700

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • France
      • Angers, France, 49933
        • Recruiting
        • Cédric ANNWEILER , MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

All patients of the University Memory Center of Angers University Hospital with respect to the eligibility criteria

Description

Inclusion Criteria:

  • All elderly patients from the University Memory Center of Angers University Hospital.
  • Able to walk without any walking aid on 15 meters
  • Mini-Mental Status Examination score > 10
  • Being affiliated to a social security regime

Exclusion Criteria:

  • Mini-Mental Status Examination score ≤ 10
  • Subject suffering from pre-existing impellent disturbances
  • History of cerebrovascular accident or other cerebro-spinal pathology
  • Poor workmanship of the written or oral French language
  • Use of walking aid such as walking frame with wheels or tricycle.
  • Acute medical or surgical disease in the past 3 months
  • Refusal to participate (or trustworthy person)
  • Near visual acuity < 2/10

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Cross-Sectional

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Group 1
Patients with Mild Cognitive Impairment
Drug: Drug intervention
before-after interventional (anti-dementia drugs and/or vitamin D) study
Other Names:
  • Anti-dementia drugs and/or vitamin D
Group 2
Patients with Mild Alzheimer's disease or related disorders
Drug: Drug intervention
before-after interventional (anti-dementia drugs and/or vitamin D) study
Other Names:
  • Anti-dementia drugs and/or vitamin D
Group 3
Patients with Moderate Alzheimer's disease or related disorders
Drug: Drug intervention
before-after interventional (anti-dementia drugs and/or vitamin D) study
Other Names:
  • Anti-dementia drugs and/or vitamin D

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Spatiotemporal gait parameters
Time Frame: baseline
baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Angers

Investigators

  • Principal Investigator: Cedric ANNWEILER, MD, Memory Centre of Angers University Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2009

Primary Completion (Anticipated)

November 1, 2017

Study Completion (Anticipated)

November 1, 2017

Study Registration Dates

First Submitted

March 11, 2011

First Submitted That Met QC Criteria

March 14, 2011

First Posted (Estimate)

March 15, 2011

Study Record Updates

Last Update Posted (Estimate)

March 15, 2011

Last Update Submitted That Met QC Criteria

March 14, 2011

Last Verified

March 1, 2011

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2009-15

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Alzheimer's Disease

Clinical Trials on Drug intervention

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Montenegro

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe